Not applicableStudy completedNCT03663647What this trial is testingAdvanced Melanoma in Russian ExperienceWho this might be right forCutaneous Melanoma, Stage IVBRAF V600 Mutation MelanomaPRO, Russia 382
Testing effectiveness (Phase 2)Study completedNCT00121225What this trial is testingVorinostat in Treating Patients With Metastatic or Unresectable MelanomaWho this might be right forCiliary Body and Choroid Melanoma, Medium/Large SizeExtraocular Extension MelanomaIris Melanoma+4 more National Cancer Institute (NCI) 32
Early research (Phase 1)Looking for participantsNCT05107674What this trial is testingNX-1607 in Adults With Advanced MalignanciesWho this might be right forOvarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer+11 more Nurix Therapeutics, Inc. 345
Early research (Phase 1)Ended earlyNCT03799003What this trial is testingASP1951 in Subjects With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumors Astellas Pharma Global Development, Inc. 119
Testing effectiveness (Phase 2)Study completedNCT01681212What this trial is testingPhase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaWho this might be right forMelanoma Bristol-Myers Squibb 21
Testing effectiveness (Phase 2)WithdrawnNCT05561491What this trial is testingONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma PatientsWho this might be right forMelanoma Targovax Oy
Testing effectiveness (Phase 2)Ended earlyNCT02302339What this trial is testingGlembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaWho this might be right forMelanoma Celldex Therapeutics 132
Testing effectiveness (Phase 2)Study completedNCT00003989What this trial is testingISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic MelanomaWho this might be right forLung CancerMelanoma (Skin) European Organisation for Research and Treatment of Cancer - EORTC 50
Testing effectiveness (Phase 2)Looking for participantsNCT05136196What this trial is testingBiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyWho this might be right forClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more National Cancer Institute (NCI)
Early research (Phase 1)Looking for participantsNCT04913285What this trial is testingEvaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsWho this might be right forSolid Tumor, AdultNon-small Cell Lung CancerMelanoma Pierre Fabre Medicament 400
Large-scale testing (Phase 3)Ended earlyNCT02967692What this trial is testingThe Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaWho this might be right forMelanoma Novartis Pharmaceuticals 568
Not applicableStudy completedNCT02492815What this trial is testingPAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced MelanomaWho this might be right forMelanoma Bristol-Myers Squibb 1,773
Early research (Phase 1)Study completedNCT01621490What this trial is testingPH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaWho this might be right forAdvanced MelanomaMetastatic Melanoma Bristol-Myers Squibb 170
Large-scale testing (Phase 3)Active Not RecruitingNCT04657991What this trial is testingA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaWho this might be right forMelanoma Pfizer 257
Testing effectiveness (Phase 2)Active Not RecruitingNCT04940299What this trial is testingTocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaWho this might be right forClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Bladder Carcinoma+39 more M.D. Anderson Cancer Center 35
Large-scale testing (Phase 3)Active Not RecruitingNCT02224781What this trial is testingDabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaWho this might be right forClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+2 more National Cancer Institute (NCI) 267
Not applicableNo Longer AvailableNCT02416232What this trial is testingAccess Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous MelanomaWho this might be right forMelanoma GlaxoSmithKline
Testing effectiveness (Phase 2)Looking for participantsNCT07280832What this trial is testingPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsWho this might be right forUnresectable Locally Advanced or Metastatic MelanomaUnresectable Locally Advanced or Metastatic Urinary Tract Tumors Shanghai JMT-Bio Inc. 500
Large-scale testing (Phase 3)Active Not RecruitingNCT05352672What this trial is testingClinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaWho this might be right forMelanoma Regeneron Pharmaceuticals 1,546
Early research (Phase 1)Study completedNCT02595866What this trial is testingTesting the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerWho this might be right forAIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more National Cancer Institute (NCI) 58